Skip to main content

Table 1 Bivariate analyses for baseline characteristics (year 2009)

From: Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity

Variable

Non-HRA cohorta(n=18,202)

HRA cohortb(n=1,017)

Pvaluec

Age Group, mean (SD)

51.6 (11.1)

49.5 (10.6)

<0.0001

Age Group, n (%)

  

<0.0001

  18-35

1,503 (8.3)

107 (10.5)

 

  36-45

3,671 (20.2)

242 (23.8)

 

  46-55

6,139 (33.7)

348 (34.2)

 

  56-65

5,331 (29.3)

274 (26.9)

 

  65+

1,558 (8.6)

46 (4.5)

 

Gender, n (%)

0.8502

  Male

4,163 (22.9)

230 (22.6)

 

  Female

14,039 (77.1)

787 (77.4)

 

Geographic Region, n (%)

  

<0.0001

  North East

2,294 (12.6)

143 (14.1)

 

  North Central

5,926 (32.6)

278 (27.3)

 

  South

6,137 (33.7)

411 (40.4)

 

  West

3,830 (21.0)

184 (18.1)

 

  Unknown

15 (0.1)

1 (0.1)

 

Employment Status, n (%)

  

<0.0001

  Employees

10,279 (56.5)

510 (50.2)

 

  Spouse/Child/Other

7,923 (43.5)

507 (49.9)

 

Insurance Type, n (%)

  

0.8176

  Fee for Service (FFS)

14,800 (81.3)

835 (82.1)

 

  Non-FFS

2,976 (16.4)

159 (15.6)

 

  Missing

426 (2.3)

23 (2.3)

 

CCI, mean (SD)

0.6 (1.1)

0.8 (1.3)

<0.0001

Any MS Symptoms, n (%) d

  

<0.0001

  Yes

12,513 (68.8)

835 (82.1)

 

  No

5,689 (31.3)

182 (17.9)

 

Any DMT Use, n (%)

  

<0.0001

  Yes

12,408 (68.2)

769 (75.6)

 

  No

5,794 (31.8)

248 (24.4)

 

All-cause ER Visits

  

<0.0001

  Yes

4,116 (22.6)

386 (38.0)

 

  No

14,086 (77.4)

631 (62.1)

 

All-cause Hospitalizations

  

<0.0001

  Yes

2,127 (11.7)

238 (23.4)

 

  No

16,075 (88.3)

779 (76.6)

 
  1. MS=multiple sclerosis; SD=standard deviation; FFS=fee for service; CCI=Charlson Comorbidity Index; DMT=disease modifying therapy; ER=emergency room.
  2. aNon-HRA cohort: MS relapse equal to 0 or 1 in year 2009.
  3. bHRA cohort: MS relapse ≥2 in year 2009.
  4. c P values of overall comparison: Chi-square for categorical variables; t-test for continuous variables.
  5. dIncluding the following list from the National Multiple Sclerosis Society: fatigue, numbness, walking (gait), balance, & coordination problems, bladder dysfunction, bowel dysfunction, visual symptoms, sexual dysfunction, dizziness and vertigo, pain, muscle weakness/spasm/spasticity, cognitive function, depression and other emotional changes, speech disorders, swallowing problems, headache, hearing loss, seizures, tremors, respiration/breathing problems, and itching.